Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
HRD
i
Other names:
Homologous Recombination Deficiency
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related biomarkers:
Others
‹
HRD + BRCA1 mutation (7)
HRD + BRCA2 mutation (7)
HRD + BRCA wild-type (6)
PTGR1 elevation + HRD (3)
HRD Signature-3 (2)
High HRD score (0)
HRD + BRCA1 mutation (7)
HRD + BRCA2 mutation (7)
HRD + BRCA wild-type (6)
PTGR1 elevation + HRD (3)
HRD Signature-3 (2)
High HRD score (0)
›
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
HRD
Fallopian Tube Cancer
HRD
Fallopian Tube Cancer
bevacizumab + olaparib
Sensitive: A1 - Approval
bevacizumab + olaparib
Sensitive
:
A1
bevacizumab + olaparib
Sensitive: A1 - Approval
bevacizumab + olaparib
Sensitive
:
A1
HRD
Peritoneal Cancer
HRD
Peritoneal Cancer
bevacizumab + olaparib
Sensitive: A1 - Approval
bevacizumab + olaparib
Sensitive
:
A1
bevacizumab + olaparib
Sensitive: A1 - Approval
bevacizumab + olaparib
Sensitive
:
A1
HRD
Peritoneal Cancer
HRD
Peritoneal Cancer
niraparib
Sensitive: A1 - Approval
niraparib
Sensitive
:
A1
niraparib
Sensitive: A1 - Approval
niraparib
Sensitive
:
A1
HRD
Fallopian Tube Cancer
HRD
Fallopian Tube Cancer
niraparib
Sensitive: A1 - Approval
niraparib
Sensitive
:
A1
niraparib
Sensitive: A1 - Approval
niraparib
Sensitive
:
A1
HRD
Ovarian Cancer
HRD
Ovarian Cancer
bevacizumab + olaparib
Sensitive: A1 - Approval
bevacizumab + olaparib
Sensitive
:
A1
bevacizumab + olaparib
Sensitive: A1 - Approval
bevacizumab + olaparib
Sensitive
:
A1
HRD
Ovarian Cancer
HRD
Ovarian Cancer
niraparib
Sensitive: A1 - Approval
niraparib
Sensitive
:
A1
niraparib
Sensitive: A1 - Approval
niraparib
Sensitive
:
A1
HRD
Prostate Cancer
HRD
Prostate Cancer
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
HRD
Prostate Cancer
HRD
Prostate Cancer
talazoparib + enzalutamide
Sensitive: A1 - Approval
talazoparib + enzalutamide
Sensitive
:
A1
talazoparib + enzalutamide
Sensitive: A1 - Approval
talazoparib + enzalutamide
Sensitive
:
A1
HRD
Ovarian Cancer
HRD
Ovarian Cancer
rucaparib
Sensitive: A2 - Guideline
rucaparib
Sensitive
:
A2
rucaparib
Sensitive: A2 - Guideline
rucaparib
Sensitive
:
A2
HRD
Ovarian Cancer
HRD
Ovarian Cancer
bevacizumab
Sensitive: A2 - Guideline
bevacizumab
Sensitive
:
A2
bevacizumab
Sensitive: A2 - Guideline
bevacizumab
Sensitive
:
A2
HRD
Ovarian Cancer
HRD
Ovarian Cancer
olaparib
Sensitive: B - Late Trials
olaparib
Sensitive
:
B
olaparib
Sensitive: B - Late Trials
olaparib
Sensitive
:
B
HRD
Ovarian Cancer
HRD
Ovarian Cancer
ABT-888
Sensitive: B - Late Trials
ABT-888
Sensitive
:
B
ABT-888
Sensitive: B - Late Trials
ABT-888
Sensitive
:
B
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.